Basic Information
BioPartners was founded in 2000 with the goal of becoming a leader in the development and commercialization of innovative formulations and novel delivery systems for first-generation biopharmaceuticals, which address significant unmet patient/healthcare needs. BioPartners aims to provide safe, effective, and competitively priced biopharmaceutical therapies. Its portfolio covers the fields of endocrinology, multiple sclerosis, oncology, and virology. Headquartered in Switzerland with a branch in Germany, BioPartners is building an international network through a series of collaborations and partnerships with leading development and service partners. BioPartners is owned by Bioton SA, a thriving Polish biotechnology company that produces clinically important drugs, including recombinant human insulin, cephalosporins, aminoglycosides, and macrolides.